111 related articles for article (PubMed ID: 31698073)
1. JNK and phosphorylated Bcl-2 predict multiple sclerosis clinical activity and glatiramer acetate therapeutic response.
Anselmo F; Tatomir A; Boodhoo D; Mekala AP; Nguyen V; Rus V; Rus H
Clin Immunol; 2020 Jan; 210():108297. PubMed ID: 31698073
[TBL] [Abstract][Full Text] [Related]
2. Phosphorylated SIRT1 as a biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis.
Ciriello J; Tatomir A; Hewes D; Boodhoo D; Anselmo F; Rus V; Rus H
Exp Mol Pathol; 2018 Oct; 105(2):175-180. PubMed ID: 30028960
[TBL] [Abstract][Full Text] [Related]
3. SIRT1 as a potential biomarker of response to treatment with glatiramer acetate in multiple sclerosis.
Hewes D; Tatomir A; Kruszewski AM; Rao G; Tegla CA; Ciriello J; Nguyen V; Royal W; Bever C; Rus V; Rus H
Exp Mol Pathol; 2017 Apr; 102(2):191-197. PubMed ID: 28109694
[TBL] [Abstract][Full Text] [Related]
4. RGC-32 as a potential biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis.
Kruszewski AM; Rao G; Tatomir A; Hewes D; Tegla CA; Cudrici CD; Nguyen V; Royal W; Bever CT; Rus V; Rus H
Exp Mol Pathol; 2015 Dec; 99(3):498-505. PubMed ID: 26407760
[TBL] [Abstract][Full Text] [Related]
5. Predictive cytokine biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis.
Valenzuela RM; Kaufman M; Balashov KE; Ito K; Buyske S; Dhib-Jalbut S
J Neuroimmunol; 2016 Nov; 300():59-65. PubMed ID: 27390072
[TBL] [Abstract][Full Text] [Related]
6. QualiCOP: real-world effectiveness, tolerability, and quality of life in patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate, treatment-naïve patients, and previously treated patients.
Ziemssen T; Calabrese P; Penner IK; Apfel R
J Neurol; 2016 Apr; 263(4):784-91. PubMed ID: 26914926
[TBL] [Abstract][Full Text] [Related]
7. Chitinase 3-like 1 is associated with the response to interferon-beta treatment in multiple sclerosis.
Matute-Blanch C; Río J; Villar LM; Midaglia L; Malhotra S; Álvarez-Cermeño JC; Vidal-Jordana A; Montalban X; Comabella M
J Neuroimmunol; 2017 Feb; 303():62-65. PubMed ID: 28063616
[TBL] [Abstract][Full Text] [Related]
8. The complement system as a biomarker of disease activity and response to treatment in multiple sclerosis.
Tatomir A; Talpos-Caia A; Anselmo F; Kruszewski AM; Boodhoo D; Rus V; Rus H
Immunol Res; 2017 Dec; 65(6):1103-1109. PubMed ID: 29116612
[TBL] [Abstract][Full Text] [Related]
9. Glatiramer acetate induces pro-apoptotic mechanisms involving Bcl-2, Bax and Cyt-c in peripheral lymphocytes from multiple sclerosis patients.
Ruggieri M; Avolio C; Scacco S; Pica C; Lia A; Zimatore GB; Papa S; Livrea P; Trojano M
J Neurol; 2006 Feb; 253(2):231-6. PubMed ID: 16184340
[TBL] [Abstract][Full Text] [Related]
10. IL-27: a potential biomarker for responders to glatiramer acetate therapy.
Mindur JE; Valenzuela RM; Yadav SK; Boppana S; Dhib-Jalbut S; Ito K
J Neuroimmunol; 2017 Mar; 304():21-28. PubMed ID: 27449853
[TBL] [Abstract][Full Text] [Related]
11. Induction of apoptosis in CD4(+) T-cells is linked with optimal treatment response in patients with relapsing-remitting multiple sclerosis treated with Glatiramer acetate.
Boziki M; Lagoudaki R; Melo P; Kanidou F; Bakirtzis C; Nikolaidis I; Grigoriadou E; Afrantou T; Tatsi T; Matsi S; Grigoriadis N
J Neurol Sci; 2019 Jun; 401():43-50. PubMed ID: 31009931
[TBL] [Abstract][Full Text] [Related]
12. 12-months prospective Pentraxin-3 and metabolomic evaluation in multiple sclerosis patients treated with glatiramer acetate.
Signoriello E; Iardino P; Casertano S; De Lucia D; Pucciarelli A; Puoti G; Chiosi E; Lus G
J Neuroimmunol; 2020 Nov; 348():577385. PubMed ID: 32927398
[TBL] [Abstract][Full Text] [Related]
13. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
[TBL] [Abstract][Full Text] [Related]
14. Effect of switching from glatiramer acetate 20 mg/daily to glatiramer acetate 40 mg three times a week on gray and white matter pathology in subjects with relapsing multiple sclerosis: A longitudinal DTI study.
Zivadinov R; Bergsland N; Hagemeier J; Tavazzi E; Ramasamy DP; Durfee J; Cherneva M; Carl E; Carl J; Kolb C; Hojnacki D; Weinstock-Guttman B
J Neurol Sci; 2018 Apr; 387():152-156. PubMed ID: 29571854
[TBL] [Abstract][Full Text] [Related]
15. Use of glatiramer acetate between 2010-2015: effectiveness, safety and reasons to start GA as first or second line treatment in Swiss multiple sclerosis patients.
Zecca C; Disanto G; Sacco R; Riccitelli GC; Gobbi C
BMC Neurol; 2019 Jul; 19(1):159. PubMed ID: 31299922
[TBL] [Abstract][Full Text] [Related]
16. Effect of glatiramer acetate on cerebral grey matter pathology in patients with relapsing-remitting multiple sclerosis.
Crescenzo F; Marastoni D; Zuco C; Pitteri M; Magliozzi R; Monaco S; Calabrese M
Mult Scler Relat Disord; 2019 Jan; 27():305-311. PubMed ID: 30453199
[TBL] [Abstract][Full Text] [Related]
17. Glatiramer acetate: long-term safety and efficacy in relapsing-remitting multiple sclerosis.
Boster AL; Ford CC; Neudorfer O; Gilgun-Sherki Y
Expert Rev Neurother; 2015 Jun; 15(6):575-86. PubMed ID: 25924547
[TBL] [Abstract][Full Text] [Related]
18. Differential glatiramer acetate treatment persistence in treatment-naive patients compared to patients previously treated with interferon.
Fernández-Fournier M; Tallón-Barranco A; Chamorro B; Martínez-Sánchez P; Puertas I
BMC Neurol; 2015 Aug; 15():141. PubMed ID: 26286576
[TBL] [Abstract][Full Text] [Related]
19. Antiapoptotic effect of c-Jun N-terminal Kinase-1 through Mcl-1 stabilization in TNF-induced hepatocyte apoptosis.
Kodama Y; Taura K; Miura K; Schnabl B; Osawa Y; Brenner DA
Gastroenterology; 2009 Apr; 136(4):1423-34. PubMed ID: 19249395
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of Delayed-release Dimethyl Fumarate on Clinical and Patient-reported Outcomes in Patients With Relapsing Multiple Sclerosis Switching From Glatiramer Acetate: RESPOND, a Prospective Observational Study.
Kresa-Reahl K; Repovic P; Robertson D; Okwuokenye M; Meltzer L; Mendoza JP
Clin Ther; 2018 Dec; 40(12):2077-2087. PubMed ID: 30470580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
